This product is a quinolone antibiotic, a broad-spectrum antibiotic. It has a significant antibacterial effect on Gram-positive bacteria (such as Staphylococcus aureus, Staphylococcus epidermidis, etc.) and Gram-negative bacteria (such as Escherichia coli, Klebsiella, etc.); it also has a good antibacterial effect on mycoplasma, chlamydia, Legionella, anaerobic bacteria including Bacteroides fragilis and Mycobacterium. Its mechanism of action is to inhibit the action of DNA gyrase in the process of bacterial DNA synthesis and play a bactericidal role.

The specific pharmacological effect is not clear from the above information

Extract from the above information

It is a cell cycle specific drug that inhibits the purine synthesis pathway. Its chemical structure is similar to that of hypoxanthine, so it can competitively inhibit the conversion process of hypoxanthine. After entering the body, this product must be converted into 6-mercaptopurine ribonucleotide by phosphoribosyltransferase in the cell before it becomes active. It has two main action links: (1) It inhibits amidotransferase through negative feedback, thereby preventing the conversion of 1-pyrophosphate-5-phosphoribosyl (PRPP) to 1-amino-5-phosphoribosyl (PRA), interfering with the initial stage of purine nucleotide synthesis. (2) Inhibits the mutual conversion between complex purines, that is, it can inhibit the conversion of inosine nucleotides to adenine nucleotides and inosine nucleotides to xanthine nucleotides and guanine nucleotides. At the same time, this product also inhibits the synthesis of coenzyme I (NAD) and reduces deoxyadenosine triphosphate (dATP) and deoxyguanosine triphosphate (dGTP) necessary for the biosynthesis of DNA, so that tumor cells cannot proliferate. This product is more sensitive to cells in the S proliferation cycle. In addition to inhibiting the synthesis of cell DNA, it also has a mild inhibitory effect on the synthesis of cell RNA. The use of mercaptopurine to treat leukemia often produces drug resistance, which may be due to the appearance of mutant leukemia cell lines in the body, which have lost the ability to convert mercaptopurine into mercaptopurine ribonucleotides.